Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Medication ’wearing off’ a bigger problem for Parkinson’s patients than physicians may realize

24.10.2003


Patients with Parkinson’s disease (PD) who are taking levodopa therapy – the most widely-used agent to treat the illness – may experience the effects of their medication “wearing off” sooner than their health care providers realize. New data presented Oct. 19 at the Parkinson’s Study Group meeting in San Francisco concluded that a specifically-designed patient questionnaire identified symptoms related to “wearing off” more frequently than a clinical assessment by a movement disorder specialist.

“Although levodopa remains the foundation of Parkinson’s disease therapy, the medical community has long recognized that its use can be limited due to the inability to control Parkinson’s disease symptoms over time,” said investigator Robert A. Hauser, M.D., M.B.A., director of the Parkinson’s Disease and Movement Disorders Center of the University of South Florida in Tampa and member of an international consortium of researchers known as the End-of-Dose Wearing Off (EODWO) Working Group. “However, this study shows that end-of-dose ‘wearing off’ may be a bigger problem for Parkinson’s disease patients than physicians and other members of the health care community realize.”

Within one to two years, almost 50 percent of PD patients receiving levodopa therapy begin to notice that their medication lasts for shorter periods, causing symptoms to re-emerge before the next dose. This phenomenon is known as “wearing off.” Eventually, the effect of a levodopa dose may decrease from eight hours when patients begin levodopa therapy to only one to two hours. “Wearing off” is associated with the re-emergence of motor symptoms (e.g. tremor and problems with balance), non-motor symptoms (e.g. anxiety, fatigue, mood changes, and restlessness), and autonomic nervous system dysfunction (e.g. sweating and hypersalivation).



“To date, the frequency of end-of-dose ‘wearing off’ in a general neurology practice is unknown, and no specific tools exist to aid clinical diagnoses of its signs and symptoms,” said Dr. Hauser. “Because there are new medications available that can help to improve symptom control throughout more of the day, it is important for physicians to have a simple way to identify these symptoms.”

A group of 10 international Movement Disorder specialists (the End-of-Dose Wearing Off Working Group) collaborated to assess prospectively whether or not a specifically designed patient questionnaire can identify the same or more subjects suffering from end-of-dose "wearing off" than a clinical assessment. The blinded study used the AliProject, a web-enabled database of patients treated at participating Parkinson’s disease research centers in the United States. The clinical database was developed by the Muhammed Ali Parkinson Research Center.

Three hundred patients diagnosed with Parkinson’s disease participated in the study. All were age 30 or older, and had Parkinson’s disease for less than 5 years. Of the 289 patients who completed the study, 87.5% were on levodopa therapy versus other anti-parkinsonian medications. The duration of levodopa therapy for these patients was 1.96+1.53 years.

Investigators found that the clinical assessment identified “wearing off” in 85 patients (29.4%) compared with 165 patients (57.1%) who self-reported symptoms of “wearing off” on the patient questionnaire. When asked about difficulties associated with these symptoms, 40% of respondents indicated that the symptoms were at least very troublesome. The most commonly listed troublesome symptoms included tremor, balance difficulty, and reduced dexterity.

Parkinson’s disease, a chronic and progressive neurological condition, affects approximately 1.5 million Americans. Symptoms include limbs that tremble; slowness of movement; stiffness and rigidity of limbs, and gait or balance problems. As the disease progresses, these symptoms usually increase and impact a person’s ability to work and function.

Marissa Emerson | University of South Florida
Further information:
http://www.hsc.usf.edu

More articles from Health and Medicine:

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

nachricht How to turn white fat brown
07.12.2016 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

NTU scientists build new ultrasound device using 3-D printing technology

07.12.2016 | Health and Medicine

The balancing act: An enzyme that links endocytosis to membrane recycling

07.12.2016 | Life Sciences

How to turn white fat brown

07.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>